down arrow

Penumbra, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US70975L1070
USD
294.72
9.01 (3.15%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

285.23296.50

52 Week

221.26310.00
Valuation
Technical
Day's Volume

CASH

90.3 k

Shareholding (Mar 2025)

FII

11.11%

Held by 183 FIIs

DII

26.93%

Held by 68 DIIs

Promoter

0.12%

How big is Penumbra, Inc.?

22-Jun-2025

As of Jun 18, Penumbra, Inc. has a market capitalization of $9.91 billion, with recent net sales of $1.24 billion and a net profit of $42.23 million. The company reported shareholder's funds of $1.15 billion and total assets of $1.53 billion as of Dec 24.

Market Cap: As of Jun 18, Penumbra, Inc. has a market capitalization of 9,911.90 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Penumbra, Inc. reported net sales of 1,240.10 million and a net profit of 42.23 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,150.93 million and total assets of 1,533.18 million.

Read More

What does Penumbra, Inc. do?

22-Jun-2025

Penumbra, Inc. is a healthcare company specializing in interventional therapies for neuro and peripheral vascular conditions, with recent net sales of $324 million and a market cap of approximately $9.91 billion. Key financial metrics include a P/E ratio of 84.00 and a return on equity of 9.83%.

Overview:<BR>Penumbra, Inc. is a healthcare company focused on interventional therapies within the Pharmaceuticals & Biotechnology industry, specifically targeting neuro and peripheral vascular medical conditions.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 324 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 39 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 9,911.90 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 84.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.30<BR>- Return on Equity: 9.83%<BR>- Price to Book: 8.17<BR><BR>Contact Details:<BR>- Address: 1 Penumbra, ALAMEDA CA : 94502-7676<BR>- Tel: 1 510 9952486<BR>- Website: http://www.penumbrainc.com/

Read More

Who are in the management team of Penumbra, Inc.?

22-Jun-2025

As of March 2022, the management team of Penumbra, Inc. includes Chairman and CEO Adam Elsesser, Chief Innovator Dr. Arani Bose, and several Independent Directors: Harpreet Grewal, Don Kassing, Janet Leeds, Bridget O'Rourke, and Surbhi Sarna. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Penumbra, Inc. includes the following individuals:<BR><BR>- Mr. Adam Elsesser, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Dr. Arani Bose, who is the Chief Innovator and a Director.<BR>- Mr. Harpreet Grewal, who is an Independent Director.<BR>- Mr. Don Kassing, who holds the position of Presiding Independent Director.<BR>- Ms. Janet Leeds, who is also an Independent Director.<BR>- Ms. Bridget O'Rourke, another Independent Director.<BR>- Ms. Surbhi Sarna, who is an Independent Director as well.<BR><BR>This team plays a crucial role in guiding the company’s strategic direction and operations.

Read More

Is Penumbra, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Penumbra, Inc. shows a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite some bearish signals in daily moving averages and mixed performance compared to the S&P 500.

As of 4 September 2025, the technical trend for Penumbra, Inc. has changed from sideways to mildly bullish. The weekly and monthly MACD indicators are bullish, while the KST shows a mildly bullish stance on the weekly and bullish on the monthly. Dow Theory also supports a mildly bullish outlook in both time frames. However, the daily moving averages indicate a mildly bearish trend, and the OBV is mildly bullish weekly but bearish monthly. <BR><BR>In terms of performance, Penumbra has returned 31.79% over the past year, significantly outperforming the S&P 500's 17.14%, but has lagged behind the index over the 3-year and 5-year periods. Overall, the current technical stance is mildly bullish, driven by the MACD and KST indicators.

Read More

Is Penumbra, Inc. overvalued or undervalued?

25-Nov-2025

As of November 21, 2025, Penumbra, Inc. is considered overvalued with a very expensive valuation grade, reflected in its high P/E ratio of 84 and EV to EBITDA of 69.41, significantly exceeding industry averages, despite a strong year-to-date return of 25.53%.

As of 21 November 2025, Penumbra, Inc. has moved from an expensive to a very expensive valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, all of which significantly exceed industry norms. Comparatively, Hologic, Inc. has a P/E of 21.83 and an EV to EBITDA of 14.71, indicating that Penumbra is trading at a premium relative to its peers.<BR><BR>Despite its strong recent performance, with a year-to-date return of 25.53% compared to the S&P 500's 12.26%, the high valuation ratios suggest that the stock may not be justified at its current price level. Overall, the combination of elevated valuation metrics and the shift in grade indicates that Penumbra, Inc. is overvalued in the current market environment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company has a low Debt to Equity ratio (avg) at times

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 19.41%

 
3

With a growth in Operating Profit of 624.09%, the company declared Very Positive results in Jun 25

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11,138 Million (Small Cap)

stock-summary
P/E

84.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.32

stock-summary
Return on Equity

11.41%

stock-summary
Price to Book

8.61

Revenue and Profits:
Net Sales:
339 Million
(Quarterly Results - Jun 2025)
Net Profit:
45 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.36%
0%
5.36%
6 Months
15.43%
0%
15.43%
1 Year
18.32%
0%
18.32%
2 Years
28.96%
0%
28.96%
3 Years
39.78%
0%
39.78%
4 Years
23.79%
0%
23.79%
5 Years
40.42%
0%
40.42%

Penumbra, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Penumbra, Inc. overvalued or undervalued?

As of 21 November 2025, the valuation grade for Penumbra, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, which are substantially higher than industry norms. In comparison, peers such as Hologic, Inc. have a P/E ratio of 21.83 and an EV to EBITDA of 14.71, showcasing a stark contrast in valuation metrics. Despite Penumbra's strong recent performance, with a year-to-date return of 21.47% compared to the S&P 500's 12.26%, the elevated valuation ratios suggest that the stock may not be justified at its current price level. The combination of these factors reinforces the conclusion that Penumbra, Inc. is overvalued in the current market....

Read More
Penumbra, Inc. Stock Hits 52-Week Low at USD 221.26

Penumbra, Inc. Stock Hits 52-Week Low at USD 221.26

Penumbra, Inc. has reached a new 52-week low of USD 221.26, reflecting recent market volatility. Despite this, the company has achieved a one-year performance of 20.28%, slightly surpassing the S&P 500. With a market cap of USD 11,138 million, Penumbra exhibits a P/E ratio of 84.00 and a return on equity of 11.41%.

Read More
Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, with its current price at $252.99. Over the past year, it achieved a 22.48% stock return, surpassing the S&P 500. Key metrics indicate a premium valuation compared to industry peers.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
19.41%
EBIT Growth (5y)
77.86%
EBIT to Interest (avg)
30.18
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.94
Tax Ratio
15.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
5.25%
ROE (avg)
3.85%
Valuation key factors
Factor
Value
P/E Ratio
84
Industry P/E
Price to Book Value
8.27
EV to EBIT
84.41
EV to EBITDA
69.41
EV to Capital Employed
11.38
EV to Sales
7.79
PEG Ratio
6.49
Dividend Yield
NA
ROCE (Latest)
13.49%
ROE (Latest)
9.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 117 Schemes (61.78%)

Foreign Institutions

Held by 183 Foreign Institutions (11.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 13.39% vs 14.49% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 175.25% vs -416.84% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "339.50",
          "val2": "299.40",
          "chgp": "13.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "46.30",
          "val2": "3.60",
          "chgp": "1,186.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-76.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "45.30",
          "val2": "-60.20",
          "chgp": "175.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "120.30%",
          "val2": "-13.40%",
          "chgp": "13.37%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.86% vs 24.96% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -84.62% vs 4,650.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,194.60",
          "val2": "1,058.50",
          "chgp": "12.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "113.50",
          "val2": "122.40",
          "chgp": "-7.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.70",
          "chgp": "-17.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-76.90",
          "val2": "-18.20",
          "chgp": "-322.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "14.00",
          "val2": "91.00",
          "chgp": "-84.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "72.20%",
          "val2": "86.70%",
          "chgp": "-1.45%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
339.50
299.40
13.39%
Operating Profit (PBDIT) excl Other Income
46.30
3.60
1,186.11%
Interest
0.30
0.30
Exceptional Items
0.00
-76.90
100.00%
Consolidate Net Profit
45.30
-60.20
175.25%
Operating Profit Margin (Excl OI)
120.30%
-13.40%
13.37%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 13.39% vs 14.49% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 175.25% vs -416.84% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,194.60
1,058.50
12.86%
Operating Profit (PBDIT) excl Other Income
113.50
122.40
-7.27%
Interest
1.40
1.70
-17.65%
Exceptional Items
-76.90
-18.20
-322.53%
Consolidate Net Profit
14.00
91.00
-84.62%
Operating Profit Margin (Excl OI)
72.20%
86.70%
-1.45%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 12.86% vs 24.96% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -84.62% vs 4,650.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Penumbra, Inc. stock-summary
stock-summary
Penumbra, Inc.
Pharmaceuticals & Biotechnology
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
Company Coordinates stock-summary
Company Details
1 Penumbra , ALAMEDA CA : 94502-7676
stock-summary
Tel: 1 510 9952486
stock-summary
http://www.penumbrainc.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."